JNJ — Johnson & Johnson

Is JNJ overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Pharmaceuticals

Overbought As of August 19, 2026

Johnson & Johnson (JNJ) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Pharmaceuticals) last closed at $273.41. The rating moved from Neutral to Overbought on August 11, 2026.

See all overbought Healthcare stocks →

AI analysis

Johnson & Johnson (JNJ) combines a diversified portfolio and strong cash generation with recent device-level product wins (AI-enabled bronchoscopy navigation) that support medium-term procedure and diagnostics growth. The company’s balance sheet and cash flow provide flexibility for shareholder returns and targeted M&A, while elevated biotech M&A activity and diagnostic demand offer potential catalysts. Key risks include regulatory outcomes, litigation exposure, payer-driven margin pressure, and execution risk on commercialization of new technologies.

Key factors

  • Diversified business mix across pharmaceuticals, medical devices, and consumer health providing stable cash flow and resilience to single-segment shocks
  • Strong balance sheet and free cash flow generation that support dividend, buybacks, and selective M&A
  • Recent product cadence and innovation in devices (MONARCH QUEST 3 AI 3D navigation for robotic bronchoscopy) supports procedure volume and diagnostic services growth
  • Favorable sector theme for diagnostic & image-guided procedures which should drive equipment and software procurement
  • Potential upside from elevated biotech/pharma M&A multiples that could make attractive assets available or increase strategic acquisition returns
  • Defensive market positioning benefits in uncertain macro environments and steady demand for essential health products

Risks

  • Regulatory and approval risk on drug and device pipelines that could delay commercial launches or limit market access
  • Litigation and legacy legal exposures that can produce large, unpredictable cash outflows
  • Payer pressure and margin compression in healthcare reimbursement (including Medicare Advantage dynamics) reducing realized pricing power
  • Intensifying competition in devices, diagnostics, and pharmaceuticals from both established peers and emerging tech-enabled entrants
  • Execution and integration risk around any large M&A or strategic partnerships
  • Slower-than-expected adoption of new device/software products or longer sales cycles in hospital procurement
  • Macroeconomic or rate-path shifts that could depress multiples or slow elective procedure volumes

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for JNJ — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.